Intensive insulin treatment of diabetic patients with myocardial infarction is highly cost-effective

[1] Packer M, Bristow MR, Cohn JN et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349–55. [2] The CIBIS II Investigators. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomised trial. Lancet 1999; 353: 9–13. [3] The MERIT-HF Investigators. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001–7. [4] Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709–17. [5] The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316(23): 1429–35. [6] The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293–302. [7] The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525–33. [8] Cohen-Solal A, Desnos M, Delahaye F, Emeriau JP, Hanania G, for the Myocardial and Heart Failure Working Group of the French Society of Cardiology, the National College of General Hospital Cardiologists and the French Geriatrics Society. A national survey of heart failure in French hospitals. Eur Heart J 2000; 21: 763–9. [9] McMurray J, McDonagh T, Morrison CE, Dargie HJ. Trends in hospitalization for heart failure in Scotland 1980–1990. Eur Heart J 1993; 14: 1158–62. [10] Reitsma JB, Mosterd A, De Craen AJ et al. Increase in hospital admission rates for heart failure in The Netherlands, 1980–1993. Heart 1996; 76: 388–92. [11] Rodriguez-Artalejo F, Guallar-Castillon P, Banegas Banegas JR, del Rey Calero J. Trends in hospitalization and mortality for heart failure in Spain, 1980–1993. Eur Heart J 1997; 18: 1771–9. [12] Petrie MC, Dawson NF, Murdoch DR, Davie AP, McMurray JJ. Failure of women’s hearts. Circulation 1999; 99: 2334–41. [13] Pitt B, Segal R, Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747–52. [14] Swedberg K, Pfeffer M, Granger C, Held P, McMurray J, Ohlin G, Olofsson B, Ostergren J, Yusuf S. Candesartan in heart failure — assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm — Programme Investigators. J Card Fail 1999; 5: 276–82. [15] Cleland JGF, Tendera M, Adamus J et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. Eur J Heart Failure 1999; 1: 211–17. [16] Torp-Pedersen C et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 1999; 341: 857–65. [17] The Study Group on Diagnosis of the Working Group on Heart Failure of The European Society of Cardiology. Increasing awareness and improving the management of heart failure in Europe: the IMPROVEMENT of HF initiative. Eur J Heart Failure 1999; 1: 139–44. 700 Editorials